<DOC>
	<DOCNO>NCT02367807</DOCNO>
	<brief_summary>This 48-week prospective observational study allow test hypothesis program pre-exposure prophylaxis ( PrEP ) administer young men color sex men ( yMSMc ) community youth drop-in center conjunction multifaceted behavioral intervention well standard HIV prevention intervention achieve least 70 % retention , well medication adherence rate significantly well previously report literature . The propose program evaluation provide critical information enhancement scale-up successful PrEP program FIGHT elsewhere effort make PrEP available grow number person risk acquire human immunodeficiency virus ( HIV ) .</brief_summary>
	<brief_title>PrEP With TDF/FTC Prevent HIV-1 Acquisition Young MSM Transgender Women Color</brief_title>
	<detailed_description>PrEP HIV prevention daily Truvada show extremely safe efficacious multiple population take consistently . Young men sex men color ( yMSMc ) comprise group high risk new HIV infection group whose HIV infection rate continue increase . New data suggest interrupt transmission among MSM reduce HIV acquisition among risk group well . However , access , link , retain yMSMc PrEP program critical successful HIV prevention historically difficult achieve . Philadelphia FIGHT initiate PrEP program youth site , Youth Health Empowerment Project ( Y-HEP ) , yMSMc approximately 1.5 year ago also give participant access general primary care . Y-HEP utilizes unique biomedical/biobehavioral approach enhance adherence retention yMSMc receive PrEP . The purpose protocol increase access safe effective PrEP yMSMc order reduce incident HIV infection health disparity HIV incidence prevalence use combine biomedical/behavioral intervention community-based set service high-risk youth Philadelphia . It hypothesize unique , combined biomedical/behavioral HIV prevention strategy lead high recruitment retention rate community set . All subject offer primary care service well package HIV risk reduction intervention include daily PrEP tenofovir emtricitabine ( TDF/FTC ) , condom , risk reduction counseling , HIV testing , sexually transmit infection ( STI ) screen treatment . A weekly support group aim maximize medication adherence retention engage subject prevention , risk-reduction behavioral counseling , education HIV , leadership training , social networking . Subjects consist 50 HIV-negative biological male age 18 30 meet eligibility criterion define . All subject receive Truvada PrEP Monday even either weekly , biweekly , monthly basis depend initial assessment need adherence support , provision obtain medication follow day ( ) Y-HEP unable attend Monday night session . Study subject consider picked medication come time week designate medication pick-up week . In addition , subject receive standard HIV prevention service include condom provision , risk reduction counseling , HIV testing , STI screen treatment , well basic medical care linkage HIV care event PrEP failure . Subjects receive behavioral intervention consist youth-focused men 's wellness service center around education HIV , adherence counseling knowledge PrEP efficacy risk behavior , general health service smoke cessation support nutritional counseling , job leadership training , sexual health well-being promotion . Subjects screen HIV , STIs , renal function baseline every three month , also rapid test HIV monthly basis ( Table 1 ) . Treatment provide STIs diagnose study , non-immune subject offer vaccine hepatitis A B. Adherence assess percentage medication pick-up visit attend well urine tenofovir level every 2-4 week plasma tenofovir level week 24 48 . Risk behavior assess STI rate adapt Risk Assessment Battery baseline , week 24 48 . A qualitative interview conduct end study assess program acceptability .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Age 18 30 year time sign informed consent Willing able independently provide write informed consent Biological male birth Tests HIV negative time screen use rapid HIV antibody test ( HIV viral load test also conduct immediately prior initiation PrEP , inclusion criterion screen lab may collect week prior medication initiation would like confirm negative viral load close medication initiation possible subject 's safety ) Willing provide locator information study staff 48week period Current participant I Am Men 's Health PrEP program willing become participant Evidence acute chronic hepatitis B infection time screen Other clinically significant acute chronic medical condition , include severe infection require treatment tuberculosis , determine study investigator Evidence renal dysfunction ( Creatinine Clearance &lt; 50 ml/min ) time screen ; Use CockcroftGault equation : GFR = ( 140Age year ) x ( Weight kg ) / ( 72 x serum creatinine ) History bone fracture explain trauma Grade 3 laboratory abnormality screen tests/assessments define DAIDS grade system Concurrent participation HIV vaccine study Known allergy/sensitivity study drug component Current use antiretroviral agent Truvada reason Experiencing decompensated cirrhosis ( e.g. , ascites , encephalopathy , etc . ) Any clinical condition prior therapy , opinion Principal Investigator , would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV prevention</keyword>
	<keyword>PrEP</keyword>
	<keyword>young men sex men</keyword>
	<keyword>Truvada</keyword>
</DOC>